Expert Interview
A look at ANAVEX 2-73 (blarcamesine) in patients with Parkinson's and Alzheimer's Disease
Ticker(s): AVXLInstitution: King's College London
- Professor and Head of Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience at King's College London, and Research Director at theCentre for Age-Related Medicine, Stavanger University Hospital
- Main research interest is the neuropsychiatric aspects of patients with neurodegenerative diseases, in particular translational studies on cognitive decline in Parkinson's disease and dementia with Lewy bodies, and is leading several national and international multi-centre research projects.
- He is Pl of European DLB Consortium, chair of the ISTAART Professional Interest Group for Lewy body dementias and Dementia theme lead of the Maudsley Biomedical Research Centre at KCL, and member of the PPM Cognitive Behavioral Working Group and NINDS Parkinson's Disease CDE on cognitive assessment.
How optimistic are you about ANAVEX 2-73(blarcamesine) given the results from the Phase 2 Clinical Trial in Parkinson’s Disease Dementia and the AVATAR Phase 3 Trial in Rett Syndrome?
Added By: sara_adminWhat mechanism of action for blarcasmine is more important, sigma-1 agonist or the muscarinic activity?
What do you make of the “calculated” ADAS-cog values calculated from MMSE reported on corporate slide deck?
Added By: jessebrodkinAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
